|
|
食管癌的免疫治疗研究进展
|
Abstract:
食管癌不论是在国内，还是在国际上均为最常见的恶性肿瘤之一。食管癌因为其早期往往可能无任何明显症状，患者发现时已经进入中晚期，导致总体预后较差。临床上，食管癌的治疗方式因受浸润程度、发生位置、病理分型、有无转移、科技技术发展、医师和医疗机构的经验，以及患者身体条件、接受程度等因素的影响，使其治疗方式千差万别。随着各个领域得不断进步，近几年，免疫检查点抑制剂作为一种新的食管癌治疗手段，取得了显著的疗效。现本文查阅了近期发表的食管癌免疫治疗相关实验及文献，围绕食管癌的免疫研究治疗进展进行综述。
Esophageal cancer is one of the most common malignant tumors both domestically and interna-tionally. Because esophageal cancer may not have any obvious symptoms in its early stage, the pa-tient has already entered the middle and late stage when it is discovered, resulting in a poor overall prognosis. Clinically, the treatment methods of esophageal cancer vary greatly due to factors such as the degree of invasion, location of occurrence, pathological type, presence or absence of metastasis, technological development, experience of doctors and medical institutions, as well as patients’ physical conditions and acceptance. Despite continuous progress in various fields, in recent years, immune checkpoint inhibitors, as a new treatment for esophageal cancer, have achieved remarka-ble efficacy. Now this article consults the recently published experiments and literatures related to immunotherapy of esophageal cancer, and summarizes the progress of immune research and treatment of esophageal cancer.
| [1] | Sung, H., Ferlay, J., Siegel, R.L., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249.
https://doi.org/10.3322/caac.21660 |
| [2] | Zheng, R., Zhang, S., Zeng, H., et al. (2022) Cancer Incidence and Mortal-ity in China, 2016. Journal of the National Cancer Center, 2, 1-9. https://doi.org/10.1016/j.jncc.2022.02.002 |
| [3] | Qiu, H., Cao, S. and Xu, R. (2021) Cancer Incidence, Mortality, and Burden in China: A Time-Trend Analysis and Comparison with the United States and United Kingdom Based on the Global Epidemiological Data Released in 2020. Cancer Communications, 41, 1037-1048. https://doi.org/10.1002/cac2.12197 |
| [4] | 宋文鹏, 王彦, 谢嘉渝, 等. 中国人饮食因素与食管癌的相关性[J]. 临床与病理杂志, 2021, 41(8): 1915-1924. |
| [5] | Cogliano, V.J., Baan, R., Straif, K., et al. (2011) Preventable Expo-sures Associated with Human Cancers. Journal of the National Cancer Institute, 103, 1827-1839. https://doi.org/10.1093/jnci/djr483 |
| [6] | Rumgay, H., Arnold, M., Laversanne, M., et al. (2021) International Trends in Esophageal Squamous Cell Carcinoma and Adenocarcinoma Incidence. The American Journal of Gastroenter-ology, 116, 1072-1076.
https://doi.org/10.14309/ajg.0000000000001121 |
| [7] | Liang, H., Fan, J.-H. and Qiao, Y.-L. (2017) Epidemiology, Etiology, and Prevention of Esophageal Squamous Cell Carcinoma in China. Cancer Biology & Medicine, 14, 33-41. https://doi.org/10.20892/j.issn.2095-3941.2016.0093 |
| [8] | Napier, K.J., Scheerer, M. and Misra, S. (2014) Esoph-ageal Cancer: A Review of Epidemiology, Pathogenesis, Staging Workup and Treatment Modalities. World Journal of Gastrointestinal Oncology, 6, 112-120.
https://doi.org/10.4251/wjgo.v6.i5.112 |
| [9] | Bleiberg, H., Conroy, T., Paillot, B., et al. (1997) Randomised Phase II Study of Cisplatin and 5-Fluorouracil (5-FU) Versus Cisplatin Alone in Advanced Squamous Cell Oesophageal Cancer. European Journal of Cancer, 33, 1216-1220.
https://doi.org/10.1016/S0959-8049(97)00088-9 |
| [10] | Lee, S.J., Kim, S., Kim, M., et al. (2015) Capecitabine in Combination with Either Cisplatin or Weekly Paclitaxel as a First-Line Treatment for Metastatic Esophageal Squamous Cell Carcinoma: A Randomized Phase II Study. BMC Cancer, 15, Article No. 693. https://doi.org/10.1186/s12885-015-1716-9 |
| [11] | Moehler, M., Maderer, A., Thuss-Patience, P.C., et al. (2020) Cisplatin and 5-Fluorouracil with or without Epidermal Growth Factor Receptor Inhibition Panitumumab for Patients with Non-Resectable, Advanced or Metastatic Oesophageal Squamous Cell Cancer: A Prospective, Open-Label, Ran-domised Phase III AIO/EORTC Trial (POWER). Annals of Oncology, 31, 228-235. https://doi.org/10.1016/j.annonc.2019.10.018 |
| [12] | Luo, H., Lu, J., Bai, Y., et al. (2021) Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients with Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical Trial. JAMA, 326, 916-925. https://doi.org/10.1001/jama.2021.12836 |
| [13] | Sun, J.-M., Shen, L., Shah, M.A., et al. (2021) Pembrolizumab plus Chemotherapy Versus Chemotherapy Alone for First-Line Treatment of Advanced Oesophageal Cancer (KEYNOTE-590): A Randomised, Placebo-Controlled, Phase 3 Study. Lancet, 398, 759-771. https://doi.org/10.1016/S0140-6736(21)01234-4 |
| [14] | Ishida, Y., Agata, Y., Shibahara, K. and Honjo, T. (1992) Induced Expression of PD-1, a Novel Member of the Immunoglobulin Gene Superfamily, Upon Programmed Cell Death. The EMBO Journal, 11, 3887-3895.
https://doi.org/10.1002/j.1460-2075.1992.tb05481.x |
| [15] | Ahmadzadeh, M., Johnson, L.A., Heemskerk, B., et al. (2009) Tumor Antigen-Specific CD8 T Cells Infiltrating the Tumor Express High Levels of PD-1 and Are Functionally Impaired. Blood, 114, 1537-1544.
https://doi.org/10.1182/blood-2008-12-195792 |
| [16] | Salmaninejad, A., Khoramshahi, V., Azani, A., et al. (2018) PD-1 and Cancer: Molecular Mechanisms and Polymorphisms. Immunogenetics, 70, 73-86. https://doi.org/10.1007/s00251-017-1015-5 |
| [17] | Sanmamed, M.F. and Chen, L. (2014) Inducible Expression of B7-H1 (PD-L1) and Its Selective Role in Tumor Site Immune Modulation. The Cancer Journal, 20, 256-261. https://doi.org/10.1097/PPO.0000000000000061 |
| [18] | Sharpe, A.H., Wherry, E.J., Ahmed, R. and Freeman, G.J. (2007) The Function of Programmed Cell Death 1 and Its Ligands in Regulating Autoimmunity and Infection. Nature Immunology, 8, 239-245. https://doi.org/10.1038/ni1443 |
| [19] | Ohaegbulam, K.C., Assal, A., Lazar-Molnar, E., Yao, Y. and Zang, X. (2015) Human Cancer Immunotherapy with Antibodies to the PD-1 and PD-L1 Pathway. Trends in Molecular Medicine, 21, 24-33.
https://doi.org/10.1016/j.molmed.2014.10.009 |
| [20] | Dong, P., Xiong, Y., Yue, J., Hanley, S.J.B. and Watari, H. (2018) Tumor-Intrinsic PD-L1 Signaling in Cancer Initiation, Development and Treatment: Beyond Immune Evasion. Frontiers in Oncology, 8, Article No. 386.
https://doi.org/10.3389/fonc.2018.00386 |
| [21] | Nunes-Xavier, C.E., Angulo, J.C., Pulido, R. and López, J.I. (2019) A Critical Insight into the Clinical Translation of PD-1/PD-L1 Blockade Therapy in Clear Cell Renal Cell Carcinoma. Current Urology Reports, 20, Article No. 1.
https://doi.org/10.1007/s11934-019-0866-8 |
| [22] | Sharpe, A.H. and Freeman, G.J. (2002) The B7-CD28 Superfam-ily. Nature Reviews Immunology, 2, 116-126.
https://doi.org/10.1038/nri727 |
| [23] | Francisco, L.M., Sage, P.T. and Sharpe, A.H. (2010) The PD-1 Pathway in Tolerance and Autoimmunity. Immunological Reviews, 236, 219-242. https://doi.org/10.1111/j.1600-065X.2010.00923.x |
| [24] | Pardoll, D.M. (2012) The Blockade of Immune Check-points in Cancer Immunotherapy. Nature Reviews Cancer, 12, 252-264. https://doi.org/10.1038/nrc3239 |
| [25] | Brunet, J.-F., Denizot, F., Luciani, M.-F., et al. (1987) A New Member of the Immunoglobulin Superfamily—CTLA-4. Nature, 328, 267-270. https://doi.org/10.1038/328267a0 |
| [26] | Lenschow, D.J., Zeng, Y., Thistlethwaite, J.R., et al. (1992) Long-Term Survival of Xenogeneic Pancreatic Islet Grafts Induced by CTLA4lg. Science, 257, 789-792. https://doi.org/10.1126/science.1323143 |
| [27] | Linsley, P.S., Wallace, P.M., Johnson, J., et al. (1992) Immunosuppression in Vivo by a Soluble Form of the CTLA-4 T Cell Activation Molecule. Science, 257, 792-795. https://doi.org/10.1126/science.1496399 |
| [28] | Chen, D.S. and Mellman, I. (2017) Elements of Cancer Immunity and the Cancer-Immune Set Point. Nature, 541, 321-330. https://doi.org/10.1038/nature21349 |
| [29] | Qureshi, O.S., Zheng, Y., Nakamura, K., et al. (2011) Trans-Endocytosis of CD80 and CD86: A Molecular Basis for the Cell-Extrinsic Function of CTLA-4. Science, 332, 600-603. https://doi.org/10.1126/science.1202947 |
| [30] | Peggs, K.S., Quezada, S.A., Chambers, C.A., Korman, A.J. and Al-lison, J.P. (2009) Blockade of CTLA-4 on Both Effector and Regulatory T Cell Compartments Contributes to the Anti-tumor Activity of Anti-CTLA-4 Antibodies. Journal of Experimental Medicine, 206, 1717-1725. https://doi.org/10.1084/jem.20082492 |
| [31] | Ribas, A. (2012) Tumor Immunotherapy Directed at PD-1. New Eng-land Journal of Medicine, 366, 2517-2519.
https://doi.org/10.1056/NEJMe1205943 |
| [32] | Janjigian, Y.Y., Shitara, K., Moehler, M., et al. (2021) First-Line Nivolumab plus Chemotherapy versus Chemotherapy Alone for Advanced Gastric, Gastro-Oesophageal Junction, and Oesophageal Adenocarcinoma (CheckMate 649): A Randomised, Open-Label, Phase 3 Trial. Lancet, 398, 27-40. https://doi.org/10.1016/S0140-6736(21)00797-2 |
| [33] | Lu, Z., Wang, J., Shu, Y., et al. (2022) Sintilimab versus Placebo in Combination with Chemotherapy as First Line Treatment for Locally Advanced or Metastatic Oesophageal Squamous Cell Carcinoma (ORIENT-15): Multicentre, Randomised, Double Blind, Phase 3 Trial. BMJ, 377, e068714. https://doi.org/10.1136/bmj-2021-068714 |
| [34] | Wang, Z.-X., Cui, C., Yao, J., et al. (2022) Toripalimab plus Chem-otherapy in Treatment-Na？ve, Advanced Esophageal Squamous Cell Carcinoma (JUPITER-06): A Multi-Center Phase 3 Trial. Cancer Cell, 40, 277-288.
https://doi.org/10.1016/j.ccell.2022.02.007 |
| [35] | Kelly, R.J., Ajani, J.A., Kuzdzal, J., et al. (2021) Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer. New England Journal of Medicine, 384, 1191-1203. https://doi.org/10.1056/NEJMoa2032125 |
| [36] | Lordick, F., Mariette, C., Haustermans, K., et al. (2016) Oesophageal Cancer: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up. Annals of Oncology, 27, v50-v57. https://doi.org/10.1093/annonc/mdw329 |
| [37] | National Comprehensive Cancer Network (NCCN) (2020) NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Esophageal and Esophagogastric Junction Cancers. Version 4. |
| [38] | National Comprehensive Cancer Network (NCCN) (2023) NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines？). Gastric Cancer. Version 2. |
| [39] | Saeed, A., Park, R., Dai, J., et al. (2023) Cabozan-tinib plus Durvalumab in Advanced Gastroesophageal Cancer and Other Gastrointestinal Malignancies: Phase Ib CAMILLA Trial Results. Cell Reports Medicine, 4, Article ID: 100916.
https://doi.org/10.1016/j.xcrm.2023.100916 |
| [40] | Cowzer, D., Wu, A.J.-C., Sihag, S., et al. (2023) Durvalumab and Pet-Directed Chemoradiation in Locally Advanced Esophageal Adenocarcinoma—A Phase Ib/II Study. Annals of Sur-gery.
https://doi.org/10.1097/SLA.0000000000005818 |
| [41] | Janjigian, Y.Y., Bendell, J., Calvo, E., et al. (2018) Check-Mate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab plus Ipilimumab in Patients with Metastatic Esoph-agogastric Cancer. Journal of Clinical Oncology, 36, 2836-2844. https://doi.org/10.1200/JCO.2017.76.6212 |
| [42] | Shitara, K., Ajani, J.A., Moehler, M., Garrido, M., et al. (2022) Nivolumab plus Chemotherapy or Ipilimumab in Gastro-Oesophageal Cancer. Nature, 603, 942-948. https://doi.org/10.1038/s41586-022-04508-4 |
| [43] | Doki, Y., Ajani, J.A., Kato, K., Xu, J.M., et al. (2022) Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma. New England Journal of Medi-cine, 386, 449-462.
https://doi.org/10.1056/NEJMoa2111380 |
